Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Share-based Compensation (2021 - 2025)

Medicinova (MNOV) has disclosed Share-based Compensation for 7 consecutive years, with -$98652.0 as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation changed N/A to -$98652.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $899608.0, a N/A change, with the full-year FY2025 number at $829095.0, down 30.43% from a year prior.
  • Share-based Compensation was -$98652.0 for Q4 2025 at Medicinova, down from $285943.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.1 million in Q1 2021 to a low of -$98652.0 in Q4 2025.
  • A 5-year average of $377070.4 and a median of $274502.0 in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: plummeted 92.89% in 2022, then surged 397.53% in 2023.
  • Medicinova's Share-based Compensation stood at $733418.0 in 2021, then plummeted by 78.42% to $158298.0 in 2022, then rose by 24.36% to $196857.0 in 2023, then surged by 156.46% to $504862.0 in 2024, then crashed by 119.54% to -$98652.0 in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Share-based Compensation are -$98652.0 (Q4 2025), $285943.0 (Q1 2025), and $504862.0 (Q3 2024).